METFORMIN XR 500 APOTEX metformin hydrochloride 500 mg modified release tablet bottle Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

metformin xr 500 apotex metformin hydrochloride 500 mg modified release tablet bottle

apotex pty ltd - metformin hydrochloride -

METFORMIN RANBAXY 1000 metformin hydrochloride 1000mg tablet blister pack Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

metformin ranbaxy 1000 metformin hydrochloride 1000mg tablet blister pack

cipla australia pty ltd - metformin hydrochloride -

METFORMIN SANDOZ metformin hydrochloride 1000mg tablets bottle Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

metformin sandoz metformin hydrochloride 1000mg tablets bottle

sandoz pty ltd - metformin hydrochloride -

METFORMIN SANDOZ metformin hydrochloride 1000mg tablets blister pack Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

metformin sandoz metformin hydrochloride 1000mg tablets blister pack

sandoz pty ltd - metformin hydrochloride -

COMPETACT 15 MG 850 MG Israeli - Kiingereza - Ministry of Health

competact 15 mg 850 mg

tzamal bio-pharma ltd - metformin hydrochloride; pioglitazone as hydrochloride - film coated tablets - metformin hydrochloride 850 mg; pioglitazone as hydrochloride 15 mg - metformin - metformin - competact is indicated as second line treatment of type 2 diabetes mellitus adult patients,particularly overweight patients, who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.after initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in hba1c). in patients who fail to show an adequate response, pioglitazone should be discontinued. in light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.

KOMBIGLYZE XR 5/500 tablets 5 mg saxagliptin (as hydrochloride) immediate release and 500 mg metformin hydrochloride modified release Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

kombiglyze xr 5/500 tablets 5 mg saxagliptin (as hydrochloride) immediate release and 500 mg metformin hydrochloride modified release

astrazeneca pty ltd - metformin hydrochloride, quantity: 500 mg; saxagliptin, quantity: 5 mg - tablet, modified release - excipient ingredients: microcrystalline cellulose; carmellose sodium; hypromellose; magnesium stearate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350; iron oxide yellow; iron oxide red; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; indigo carmine aluminium lake; ethanol; shellac; sulfuric acid - kombiglyze xr is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate (see clinical trials and dosing and administration for data on combinations studied).

KOMBIGLYZE XR 5/1000 tablets 5 mg saxagliptin (as hydrochloride) immediate release and 1000 mg metformin hydrochloride modified release Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

kombiglyze xr 5/1000 tablets 5 mg saxagliptin (as hydrochloride) immediate release and 1000 mg metformin hydrochloride modified release

astrazeneca pty ltd - metformin hydrochloride, quantity: 1000 mg; saxagliptin, quantity: 5 mg - tablet, modified release - excipient ingredients: hypromellose; carmellose sodium; magnesium stearate; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; indigo carmine aluminium lake; ethanol; shellac; sulfuric acid; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350 - kombiglyze xr is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate (see clinical trials and dosing and administration for data on combinations studied).

KOMBIGLYZE XR 2.5/1000 tablets 2.5 mg saxagliptin (as hydrochloride) immediate release and 1000 mg metformin hydrochloride modified release Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

kombiglyze xr 2.5/1000 tablets 2.5 mg saxagliptin (as hydrochloride) immediate release and 1000 mg metformin hydrochloride modified release

astrazeneca pty ltd - metformin hydrochloride, quantity: 1000 mg; saxagliptin, quantity: 2.5 mg - tablet, modified release - excipient ingredients: hypromellose; magnesium stearate; carmellose sodium; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; indigo carmine aluminium lake; ethanol; shellac; sulfuric acid; iron oxide yellow - kombiglyze xr is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate (see clinical trials and dosing and administration for data on combinations studied).

NESINA MET 12.5/1000; 12.5 mg alogliptin (as benzoate) / 1000 mg metformin hydrochloride film-coated tablets blister pack Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

nesina met 12.5/1000; 12.5 mg alogliptin (as benzoate) / 1000 mg metformin hydrochloride film-coated tablets blister pack

takeda pharmaceuticals australia pty ltd - metformin hydrochloride, quantity: 1000 mg; alogliptin benzoate, quantity: 17 mg (equivalent: alogliptin, qty 12.5 mg) - tablet, film coated - excipient ingredients: povidone; microcrystalline cellulose; hypromellose; crospovidone; mannitol; purified talc; titanium dioxide; iron oxide yellow; magnesium stearate - nesina met is indicated to improve glycaemic control in adult patients (> or = 18 years old) with type 2 diabetes mellitus when diet and exercise do not provide adequate glycaemic control and treatment with both alogliptin and metformin is appropriate,,- when treatment with metformin alone does not provide adequate control; or - in combination with a thiazolidinedione or with insulin, when dual therapy does not provide adequate control.,nesina met can also be used to replace separate tablets of alogliptin and metformin in patients already being treated with this combination.

NESINA MET 12.5/500; 12.5 mg alogliptin (as benzoate) / 500 mg metformin hydrochloride film-coated tablets blister pack Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

nesina met 12.5/500; 12.5 mg alogliptin (as benzoate) / 500 mg metformin hydrochloride film-coated tablets blister pack

takeda pharmaceuticals australia pty ltd - metformin hydrochloride, quantity: 500 mg; alogliptin benzoate, quantity: 17 mg (equivalent: alogliptin, qty 12.5 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; mannitol; titanium dioxide; magnesium stearate; iron oxide yellow; purified talc; crospovidone; povidone; hypromellose - nesina met is indicated to improve glycaemic control in adult patients (> or = 18 years old) with type 2 diabetes mellitus when diet and exercise do not provide adequate glycaemic control and treatment with both alogliptin and metformin is appropriate,,- when treatment with metformin alone does not provide adequate control; or - in combination with a thiazolidinedione or with insulin, when dual therapy does not provide adequate control.,nesina met can also be used to replace separate tablets of alogliptin and metformin in patients already being treated with this combination.